Citius Oncology (CTOR) & Its Peers Critical Review

Citius Oncology (NASDAQ:CTOR) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its rivals? We will compare Citius Oncology to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, profitability, earnings and analyst recommendations.

Volatility & Risk

Citius Oncology has a beta of 2.98, suggesting that its share price is 198% more volatile than the S&P 500. Comparatively, Citius Oncology’s rivals have a beta of 0.90, suggesting that their average share price is 10% less volatile than the S&P 500.

Profitability

This table compares Citius Oncology and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-65.79%	-26.15%
Citius Oncology Competitors	-906.16%	-572.54%	-29.84%

Analyst Ratings

This is a breakdown of recent recommendations for Citius Oncology and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	2	0	2.33
Citius Oncology Competitors	6644	12473	38222	1215	2.58

Citius Oncology presently has a consensus price target of $6.00, suggesting a potential upside of 479.71%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 53.38%. Given Citius Oncology’s higher possible upside, analysts clearly believe Citius Oncology is more favorable than its rivals.

Earnings and Valuation

This table compares Citius Oncology and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Citius Oncology	N/A	-$24.76 million	-3.04
Citius Oncology Competitors	$896.91 million	-$44.22 million	10.30

Citius Oncology’s rivals have higher revenue, but lower earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 6.7% of Citius Oncology shares are owned by company insiders. Comparatively, 13.4% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Citius Oncology beats its rivals on 8 of the 13 factors compared.

Citius Oncology Company Profile

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.